Physician profile
Leslie Perla
NPI 1467444067
$3,376.11
in general payments reported to CMS, 2019-2025
29 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $80.94 · 2021: $15.14 · 2022: $89.79 · 2023: $501 · 2024: $960 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,324 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,323.56 |
| Education | $274.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $933.44 | 2023-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $363.11 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $300.07 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.57 | 2019-2025 | Xifaxan |
| Qol Medical, LLC | $246.01 | 2019-2024 | Sucraid, Sucraid |
| Lilly USA, LLC | $124.77 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $121.23 | 2024-2025 | |
| Celltrion USA INC. | $114.43 | 2024-2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $96.18 | 2019-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $82.42 | 2024 | |
| Romark Laboratories, Lc | $72.88 | 2019 | |
| Phathom Pharmaceuticals, INC. | $65.24 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $64.54 | 2025 | Rezdiffra |
| Allergan, INC. | $57.54 | 2019 | |
| Phadia US INC. | $54.73 | 2023-2024 | Immunocap |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $54.51 | 2022-2023 | Zeposia |
| Pfizer INC. | $50.45 | 2024-2025 | |
| Ardelyx, INC. | $42.61 | 2024-2025 | Ibsrela |
| Boston Scientific Corporation | $37.76 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $35.53 | 2019-2020 | |
| Braintree Laboratories, INC. | $34.75 | 2025 | Sutab, Suflave |
| Genzyme Corporation | $28.81 | 2024 | |
| Daiichi Sankyo INC. | $24.97 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.73 | 2023 | Dupixent |
| Nestle Healthcare Nutrition INC. | $24.40 | 2023 | |
| Ironwood Pharmaceuticals, INC | $19.68 | 2024 | |
| Vivus LLC | $17.15 | 2024 | Pancreaze |
| Redhill Biopharma INC. | $15.75 | 2020 | |
| Evoke Pharma, INC. | $13.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Perla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.